Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTY 1
2016-003727-27Phase 3Completed
- Sponsor
- Myovant Sciences
- Start
- Mar 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tissue-plasminogen activator, estradiol and norethisterone acetate in Fibromyoma (LM) (3 arms), sponsored by Myovant Sciences. Primary endpoint: Menstrual blood loss responder rate in Group A versus Group C. Started Mar 2017; status: completed.
02
Drugs
tissue-plasminogen activatorestradiolnorethisterone acetate
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on 2016-003727-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003727-27.